Melperone

Melperone

SCHEMBL146287

CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 1.00
MEN1 O00255 1/20 1.00
CHRM2 P08172 1/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00
DRD1 P21728 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00
KCNH2 Q12809 1/20 1.00
HRH3 Q9Y5N1 1/20 1.00
TSHR P16473 1/20 0.71
DRD2 P14416 4/20 0.69
CYP2D6 P10635 1/20 0.67
HTR2A P28223 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Melperone SCHEMBL1649537 0.99 KMT2A (0.97) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL20254428 0.87 MEN1 (0.78) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL13913702 0.87 KMT2A (0.78) KMT2AMEN1CHRM2HTR1AADRA2A
Hydrochloric Acid SCHEMBL30658979 0.86 MEN1 (0.76) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL22778808 0.86 HTR1A (0.76) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL11415059 0.86 MEN1 (0.76) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL4491395 0.86 KMT2A (0.76) KMT2AMEN1CHRM2HTR1AADRA2A
Lenperone SCHEMBL121686 0.85 MEN1 (0.74) KMT2AMEN1CHRM2HTR1AADRA2A
SCHEMBL16986166 0.84 TSHR (0.97) KMT2AMEN1CHRM2HTR1AADRA2A
Haloperidol SCHEMBL7568612 0.84 DRD2 (0.84) KMT2AMEN1CHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4087 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3507371-B1 COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM UNIV RUTGERS (US) 2026-01-28 EP claimed
US-12527754-B2 Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions TUFTS MEDICAL CENTER, INC. (US) 2026-01-20 US claimed
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
EP-4618973-A1 METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT Sumitomo Pharma America, Inc. (US) 2025-09-24 EP claimed
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 AUSPEX PHARMACEUTICALS LLC 2025-06-05 US claimed
EP-4223760-B1 HETEROAROMATIC NMDA RECEPTOR MODULATOR AND USES THEREOF NOVARTIS AG (CH) 2025-06-04 EP claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025101418-A1 TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT ALTO NEUROSCIENCE, INC. (US) 2025-05-15 WO claimed
US-20250144092-A1 TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT ALTO NEUROSCIENCE, INC. 2025-05-08 US claimed
WO-2025080415-A1 TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM ALTO NEUROSCIENCE, INC. (US) 2025-04-17 WO claimed
EP-0891180-A1 PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS WARNER-LAMBERT COMPANY (US) 1999-01-20 EP claimed
WO-1998043646-A1 NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS AKZO NOBEL N.V. (NL) 1998-10-08 WO claimed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO claimed
CN-1170346-A Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process WARNER LAMBERT CO (US) 1998-01-14 CN claimed
WO-1998000159-A1 USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS OXIGENE, INC. (US) 1998-01-08 WO claimed
EP-0695172-B1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF UNIV GENT (BE) 1997-12-17 EP claimed
WO-1997037629-A1 PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS WARNER-LAMBERT COMPANY (US) 1997-10-16 WO claimed
EP-0695172-A1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) 1996-02-07 EP claimed
WO-1994023700-A1 HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF RIJKSUNIVERSITEIT GENT LABORATORIUM VOOR FARMACEUTISCHE TECHNOLOGIE (BE) 1994-10-27 WO claimed
US-5221679-A Useful for those patient who had experienced inadequate clinical response or adverse effects from, clozapine and or neuroleptic drugs CASE WESTERN RESERVE UNIVERSITY (US) 1993-06-22 US claimed